A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Trial ID # NCT02498912
Phase I
Drug Class Immunotherapy: Cellular Therapy
Drug Name 4H11-28z/fIL-12/EFGRt+ CAR T
Alternate Drug Names 4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes
Drugs in Trial 4H11-28z/fIL-12/EFGRt+ CAR T, Cyclophosphamide, Fludarabine
Eligible Participant

MUC16ecto+ recurrent high grade serous ovarian cancer (> 2 prior therapies)

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, evaluated per RECIST


DCR: 44% (8SD, n=18)

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:


IV and IP CAR T cell therapy is safe in the absence of chemotherapy, but toxicity is observed when the CAR T cells are given post-lymphodepleting chemotherapy


O'Cearbhaill RE et al: A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC). SGO (2020) abstract 54

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.